

International Journal of Universal Pharmacy and Bio Sciences 8(4): July-August 2019
**INTERNATIONAL JOURNAL OF UNIVERSAL
PHARMACY AND BIO SCIENCES**

IMPACT FACTOR 4.018***

ICV 6.16***

Pharmaceutical Sciences

Research Article.....!!!

**SIMULTANEOUS ESTIMATION OF ALOGLIPTIN BENZOATE AND
MEFORMIN HYDROCHLORIDE IN BULK AND COMBINED TABLET DOSAGE
FORM BY UV-SPECTROPHOTOMETRIC METHODS**

Poornima A.N*, Dr. A Geethalakshmi, Shilpashree A T, Pavan Kumar H.K

Department of Pharmaceutical Chemistry, R.R College of Pharmacy, Bangalore-560090, Karnataka, India.

ABSTRACT

KEYWORDS:

Alogliptin benzoate,
Meformin hydrochloride,
Simultaneous equation
method, Second order
derivative method.

FOR CORRESPONDENCE:

Poornima A.N *



ADDRESS:

Department of Pharmaceutical
Chemistry, R.R College of
Pharmacy, Bangalore-560090,
Karnataka, India.

Two simple, accurate, rapid and precise UV Spectrophotometric methods have been developed for simultaneous estimation of Alogliptin benzoate (ALO) and Meformin hydrochloride (MET) in combined tablet dosage form. The methods employed were (A) Simultaneous equation and (B) Second order derivative method. Method-A involves which involved measuring the absorbance values at 277 nm and 232 nm of overlay spectrum of ALO & MET respectively. Method B is Second order derivative spectrophotometry, which involved measuring the absorbance values at 277 nm and 232 nm of second derivative spectrum of ALO & MET respectively. In both the methods linearity was found in the concentration range of 0.5-2.5 µg/ml and 5-25 µg/ml respectively. Both the methods were found to be rapid, specific, precise and accurate. Hence these methods can be applied for routine analysis of ALO and MET in combined dosage form without any interference by the excipients. The above methods are validated according to ICH guidelines.

INTRODUCTION:

Alogliptin is an orally administered anti-diabetic drug in the DPP-4 inhibitor class. Alogliptin inhibits dipeptidyl peptidase 4 (DPP-4), which normally degrades the incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP-1). The inhibition of DPP-4 increases the amount of active plasma incretins which helps with glycemic control. Only one liquid chromatography method has been reported for the estimation of Alogliptin individually. No other methods are available for individual drug and in any combinations.

**Figure 1: Chemical structure of ALO:****Figure 2: Chemical structure of MET**

Metformin is a biguanide antihyperglycemic agent used for treating non-insulin-dependent diabetes mellitus [NIDDM]. It improves glycemic control by decreasing hepatic glucose production, decreasing glucose absorption and increasing insulin-mediated glucose uptake. Metformin may induce weight loss and is the drug of choice for obese NIDDM patients. There are very few reports on analytical methods for estimation of Metformin individually and in other combinations, which includes bio analytical methods using rat plasma, RP-HPLC, Spectrophotometric methods. The combination of Alogliptin and Metformin was significantly superior with proper diet and high blood sugar. On literature survey, it was found that no method has been reported for simultaneous estimation of Alogliptin and Metformin in combined dosage form and no method is available in pharmacopeia. Hence an attempt has been made to develop a simple, accurate, precise and reproducible Q absorbance ratio and area under curve methods for simultaneous estimation of ALO and MET in combined dosage form and the same has been validated as per recommended ICH guidelines.

2. EXPERIMENTAL**2.1 Apparatus:**

A Shimadzu model 1800 (Japan) double beam UV/Visible spectrophotometer with spectral width of 2 nm, wavelength accuracy of 0.5 nm and a pair of 10 mm matched quartz cell was used to measure absorbance of all the solutions. Spectra were automatically obtained by UV-Probe system software. An Electronic balance of capacity 220g SHIMADZU COOPRATION JAPAN.

2.2 Preparation of standard stock solutions: 100 mg each of Alogliptin benzoate and Metformin hydrochloride were weighed separately and transferred in two different 100 ml volumetric flasks. Both the drugs were dissolved in 50 ml of solvent by ultrasonication and then volume was made up to the mark with Solvent to obtain concentration of 1000 µg/ml of each component (stock A and A' solution). From the above stock A and A' solution 10 ml of aliquot was pipetted out into a 100 ml volumetric flask and the volume was made up to the mark with solvent to obtain the final concentration of 100µg/ml of each component (stock B and B' solution).

2.3 Preparation of sample stock solution using formulation: Twenty tablets of Alogliptin benzoate and Metformin hydrochloride (KAZONO) in combination were weighed and their average weight was determined. The tablets were crushed to fine powder and from the triturate, tablet powder equivalent to 25 mg of Alogliptin benzoate was weighed which also contains 250 mg of Metformin hydrochloride and transferred to 100 ml volumetric flask and dissolved in 50 ml solvent and the content was kept in ultrasonicator for 15 min. The solution was filtered through Whatmann filter paper No.41, finally the volume was made up to the mark with solvent, which gave a concentration of 250 μ g/ml of Alogliptin benzoate and 2500 μ g/ml of Metformin hydrochloride and this solution was used as stock 'A' solution. From the above stock 'A' solution, 5 ml of the aliquot was pipetted out and was transferred to a 50 ml volumetric flask. The volume was made upto 50 ml with solvent to obtain a solution with final concentration of 25 μ g/ml Alogliptin benzoate and 250 μ g/ml of Metformin hydrochloride (stock B).

2.4 Methods:

METHOD A: SIMULTANEOUS EQUATION METHOD:- From the standard stock B and B' solutions, dilutions ranging between 1-90 μ g/mL for both the drugs were prepared and scanned in the wavelength range of 400-200 nm using UV- visible spectrophotometer. At 277 nm Alogliptin benzoate showed maximum absorbance and at 232 nm Metformin hydrochloride shows maximum absorbance. Both the drugs did not show any interference at either of the wavelength. Hence 277 nm and 232 nm for Alogliptin benzoate and Metformin hydrochloride were selected as the working analytical wavelength.

METHOD B: SECOND ORDER DERIVATIVE METHOD:- From the standard stock B and B' solutions, dilutions ranging between 0.5 to 2.5 μ g/mL of Alogliptin benzoate and 5 to 25 μ g/mL of Metformin hydrochloride were prepared and scanned in the wavelength range of 400-200 nm using UV Spectrophotometer. The absorbance spectrum, thus obtained were derivatized to remove the interference of absorbing species. From the examination of the second order derivative spectrum of Alogliptin benzoate and Metformin Hydrochloride, 277nm (λ_1) and 232nm (λ_2) were selected as working wavelengths for the second order derivative spectroscopy.

2.5 Validation of the methods:-All the methods were validated according to ICH guidelines by carrying out analysis of six replicate samples of tablet. Recovery studies were carried out at three different levels i.e., 80%, 100% and 120% by adding the pure drug to previously analyzed tablet powder sample. From the amount of drug found, percentage recovery was calculated.

3 Results and Discussion:- The estimation of Alogliptin benzoate and Metformin hydrochloride in tablet formulation was found to be accurate and reproducible with a linearity of 0.5 to 2.5 μ g/mL and 5 to 25 μ g/mL respectively for both the methods and the correlation coefficient 0.998 and 0.999 for method A and 0.998 and 0.998 for method B. The optical characteristics such as linearity range, molar

absorptivity, percentage relative standard deviation of recovery studies and precision in each method were calculated and the results were reported in Table 1 and Table 2 for method A and method B respectively. Also the regression characteristics like slope (m), intercept (c) and correlation coefficient (r) were calculated and are presented in Table 1 and Table 2 for method A and method B respectively. The accuracy was found by recovery studies at three different levels i.e. 80%, 100% and 120%. The values of standard deviation were satisfactory and the recovery studies were close to 100%. The % RSD value was less than 2, an indicative of the accuracy of the methods.

The results of Formulation were reported in Table-3. The spectra of Alogliptin benzoate, Metformin hydrochloride and formulation are reported by Simultaneous Estimation method (Fig. 3, 4 and 5) and calibration curve was plotted (Fig. 6, 7, 8 and 9).




Fig. 3: Overlay Spectrum of Alogliptin benzoate at 277 nm in Distilled water.




Fig. 4: Overlay Spectra of Metformin hydrochloride at 232 nm in Distilled water.




Fig. 5: Overlay Spectra of Formulation in Distilled water in Distilled water.




Fig. 6 & 7: Calibration curve for **Alogliptin benzoate at 277 nm** and **Metformin hydrochloride at 232 nm** by Simultaneous Equation Method.




Fig.8 & 9: Calibration curve for **ALO in Formulation at 277 nm** & **MET in Formulation at 232 nm** by Simultaneous Equation Method.

The **Second order derivative spectrum of ALO at 277 nm**, **MET at 232 nm** and **formulation** are reported (Fig.10,11,12) and calibration curve was plotted (Fig.13,14, 15,16).




Fig. 10: **Second order derivative spectrum of ALO at 277 nm.**




Fig. 11: Second order derivative spectrum of MET at 232 nm.




Fig 12: Second order derivative spectrum of ALO and MET in Formulation at 232 and 277 nm.





Fig. 13 & 14: Calibration curve for ALO at 277nm and MET at 232 nm by Second Order Derivative Method.





Fig. 15 & 16: Calibration curve for ALO in Formulation at 277 nm & MET in Formulation at 232 nm by Second Order derivative Method.

Table1: Optical characteristics and other parameters for Method A

Parameters		ALO	MET
Linear range ($\mu\text{g/ml}$)		0.5 - 2.5	5 - 25
λ_{max} /wavelengthrange(nm)		277 nm	232 nm
Coefficient of correlation		0.9998	0.9999
Slope*(m)		0.1917	0.017
Intercept*(c)		0.0084	0.0004
Accuracy (%RSD)	80%	0.0472	0.02081
	100%	0.0611	0.01527
	120%	0.1201	0.01
Precision (%RSD)	Intra-day	0.1720	0.5091
	Inter-day	0.0159	0.0001
Limit of Detection ($\mu\text{g/ml}$)		0.014	0.043
Limit of Quantification ($\mu\text{g/ml}$)		0.229	0.699

* $y=mx+c$; when x is the concentration in $\mu\text{g/ml}$ and y is absorbance unit.

Table2: Optical characteristics and other parameters for Method B

Parameters		ALO	MET
Linear range ($\mu\text{g/ml}$)		0.5 - 2.5	5 - 25
λ_{max} /wavelengthrange(nm)		277 nm	232 nm
Coefficient of correlation		0.9998	0.9999
Slope*(m)		-0.0089	-0.0012
Intercept*(c)		0.0001	0.0002
Accuracy (%RSD)	80%	0.0472	0.02081
	100%	0.0611	0.01527
	120%	0.1201	0.01
Precision (%RSD)	Intra-day	0.079	0.1715
	Inter-day	0.04	0.01
Limit of Detection ($\mu\text{g/ml}$)		0.207	0.277
Limit of Quantification ($\mu\text{g/ml}$)		0.63	0.841

* $y=mx+c$; when x is the concentration in $\mu\text{g/ml}$ and y is absorbance unit.

Table 3: Results of formulation

method	Brand name	Label claim of ALO (mg)	Label claim of MET (mg)	Amount found for ALO (mg)	Amount found for MET (mg)	%Recovery \pm SD** for ALO	%Recovery \pm SD** for MET
A	Kazano	25	250	25.015	249.863	99.84 \pm 0.42780	99.95 \pm 0.01505
B		25	250	25.005	249.888	100.04 \pm 0.2245	99.96 \pm 0.02345

** Average of six determinations.

3. CONCLUSION:-

All these factors leads to conclusion that proposed absorption correction method is found to be simple, sensitive, accurate and precise and can be used for routine analysis of ALO and MET as compare to the developed simultaneous equation by matrix. The developed method was validated as per ICH guidelines. Statistical analysis proved that the methods is repeatable and selective for the analysis of ALO and MET in their combined pharmaceutical formulations.

4. ACKNOWLEDGEMENT:-

The authors are express their gratitude to the R.R College of Pharmacy, Bangalore, Karnataka for providing all the facilities and Swapnroop drug & pharmaceuticals Aurangabad, Maharashtra and Aarti drugs Ltd goa, India for providing gift sample of ALO and MET. The authors are also thankful to Vision Group of Science and Technology, Govt of Karnataka for their grants to our college.

5. REFERENCES:

1. <http://www.drugbank.ca/drugs/DB06203/2013/> November.
2. Ramzia I E, Ehab F E, Bassam M A. Liquid Chromatographic determination of Alogliptin in bulk and in its pharmaceutical preparation. Int J Biomed Sc, September 2012;8(3):215-8.
3. Laurene L B, Jhon S L, Keith L P. Goodman and Gilman's the pharmacological basis of Therapeutics. 11th ed. Mc Graw Hill, New York, U.S.A; 2006. p. 1638-39.
4. John H B, John M B. Wilson & Gisvold's textbook of Organic medicinal and Pharmaceutical Chemistry. 11th ed. 2004; p. 672.
5. Indian Pharmacopoeia. 2007(2):1359.
6. British Pharmacopoeia. 2003(2):1219, S-68.
7. Wanjari M M, There A W, Tajne M R, Chopde C T, Umathe S N. Rapid and simple RPHPLC method for the estimation of Metformin in rat plasma. Indian J Pharm Sci. Mar-Apr2008;70(2):198-202.
8. Maria C R, Mihaela I, Lavinia H, Elena I, Valentina A, Aurelian E R. et al. Constantin M. Validation of a HPLC method for the simultaneous analysis of Metformin and Gliclazide in human plasma. FARMACIA. 2009;57(6):728-35.

9. I.H.I. Habib, M.S. Kamel, *Talanta*, 2003, 60,185-190.
10. Sujana K, Swathi R G, Bhanu P M, Saheethi R M. Simultaneous estimation of Pioglitazone Hydrochloride and Metformin Hydrochloride using UV spectroscopic method in tablet dosage form. *J Biomed Sci & Res.* 2010;2(2):110-5.
11. Dhabale P N, Seervi C R. Simultaneous UV Spectrophotometric Method for Estimation of Gliclazide and Metformine Hydrochloride in tablet dosage form. CODEN (USA) IJCRGG. April-June 2010;2(2):813-7.
1. Amruta B L, Minal R G, Sawant S D. Simultaneous UV spectrophotometric method for estimation of Sitagliptin Phosphate and Metformin Hydrochloride in bulk and tablet dosage form. *Der Pharma Chemical.* 2012;4(3):854-9.